綠葉製藥(02186.HK)附屬博安生物引入3家投資者 投前估值48.50億元
格隆匯12月28日丨綠葉製藥(02186.HK)宣佈,蘇州工業園區新建元三期創業投資企業(有限合夥)、深圳市柏奧瑞思投資合夥企業(有限合夥)及煙台創科新動能投資中心(有限合夥)(統稱“投資者”)各自有條件同意作出投資並認購山東博安生物技術有限公司(“山東博安”)的部分註冊資本。山東博安為一家於中華人民共和國成立的有限公司,是公司的附屬公司。投資乃按山東博安的融資前估值約人民幣48.50億元為基礎得出。
山東博安於2013年成立,是一家全面綜合性生物製藥公司。其專門從事治療用抗體開發,專注於腫瘤、免疫性、疼痛及內分泌疾病。在過去幾年,山東博安在抗體生產、先導優化物、細胞系建立、工藝開發、技術轉讓、中試生產及商業化生產方面積累了豐富的經驗。山東博安的抗體發現活動圍繞四個平台展開,即全人抗體轉基因小鼠及噬菌體展示技術、雙特異性T細胞銜接系統技術、抗體偶聯技術及納米抗體平台。其涵蓋靶點驗證、抗體發現與開發、化學、製造和控制的全過程。獨立一致的研發能力確保抗體品質優、開發速度快及供應商依賴性低。
山東博安已開發出10多個擁有國際知識產權保護的創新抗體和8個生物類似藥。生物類似藥方面,LY01008(Avastin的生物類似藥)已申報中國上市申請;LY06006(Prolia的生物類似藥)處於中國III期臨牀及歐美I期臨牀;LY09004(Eylea的生物類似藥)及LY01011(Xgeva的生物類似藥)處於中國III期臨牀。此外,一種創新抗體產品已進入中國I期臨牀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.